

PARP INHIBITORS - COMPETITIVE LANDSCAPE, PIPELINE AND MARKET ANALYSIS, 2018

<https://marketpublishers.com/r/P311ABBA6D0EN.html>

Date: October 2018

Pages: 159

Price: US\$ 3,000.00 (Single User License)

ID: P311ABBA6D0EN

Abstracts

This report can be delivered to the clients within 48 hours

'PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 15+ products along with 12+ companies involved. AbbVie and Pfizer are among the developers of most promising pipeline products.

Products covered by Phase

Marketed Products

Phase III, Phase II and Phase I

IND and Pre-clinical

Overview of pipeline development activities for PARP Inhibitors

Pipeline analysis of 15+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for PARP Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of PARP Inhibitors

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for PARP Inhibitors

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the PARP Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for PARP Inhibitors and also provide company profiling

Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario PARP Inhibitors to formulate effective R&D strategies

Assess challenges and opportunities that influence PARP Inhibitors R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding PARP Inhibitors pipeline depth and focus of target therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for PARP Inhibitors to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

- Executive Summary
- Collaboration, Acquisitions and Licensing
- Table of Contents
- Overview
- Poly (ADP-Ribose) Polymerase
- Structure and Function of PARP1
- PARP Homologs
- Functions of PARP
- Role in DNA Repair
- Function in Chromatin Remodeling
- Effects on Transcription Factors and Epigenetic Factors
- PARP Inhibitor
- Market Overview
- Comparative Analysis of Pipeline & Marketed Products
- Marketed Drug Candidate Profiles
- Zejula: Tesaro
- Product Description
- Research and Development
- Zejula Heat Map
- Product Development Activities
- Zejula Heat Map
- Forecasted Sales for Zejula
- Zejula Analyst Insights
- (The list continues)
- Market Positioning of PARP Inhibitors
- PARP Inhibitors Market Evolution
- PARP Inhibitors Class Share Evolution
- Pipeline Therapeutics
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Veliparib: Abbvie
- Product Description
- Research and Development
- Product Development Activities
- Forecasted Sales for Veliparib
- Veliparib Analyst Insights
- (The list continues)

Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Appendix

List Of Tables

LIST OF TABLES

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2018-2023)

Table 3: Historical and Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2018-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Table 13: Assessment by Monotherapy Products for PARP Inhibitors

Table 14: Assessment by Route of Administration for PARP Inhibitors

Table 15: Assessment by Stage and Route of Administration for PARP Inhibitors

Table 16: Dormant Products

Table 17: Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1: Structural and functional characteristics of PARP1
- Figure 2: PARP Family of Proteins
- Figure 3: Role of PARP1 in Base Excision Repair (BER)
- Figure 4: Role of PARP1 in Transcription Regulation
- Figure 5: PARP Inhibition
- Figure 6: Marketed and Pipeline products for PARP Inhibitors
- Figure 7: Forecasted Sales for Zejula (2018-2023)
- Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)
- Figure 9: Forecasted Sales for Rubraca (2018-2023)
- Figure 10: Market Evolution of PARP Inhibitors (2014-2023)
- Figure 11: Total Drugs for PARP Inhibitors
- Figure 12: Late Stage Products (Phase III)
- Figure 13: Forecasted Sales for Veliparib (2018-2023)
- Figure 14: Forecasted Sales for Talazoparib (2018-2023)
- Figure 15: Mid Stage Products (Phase II)
- Figure 16: Early Stage Products (Phase I)
- Figure 17: Pre-clinical Stage
- Figure 18: Assessment by Monotherapy
- Figure 19: Assessment by Route of Administration
- Figure 20: Assessment by Stage and Route of Administration
- Figure 21: Dormant Products
- Figure 22: Discontinued Products

I would like to order

Product name: PARP INHIBITORS - COMPETITIVE LANDSCAPE, PIPELINE AND MARKET ANALYSIS, 2018

Product link: <https://marketpublishers.com/r/P311ABBA6D0EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P311ABBA6D0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

